Location Directory

Clinical trials in Cleveland, Ohio

This page shows live ClinicalTrials.gov search results for Cleveland, Ohio, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

11338

Shown on this page

Current sort

Institutions in Cleveland

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Cleveland Clinic

Live official records

Open in full search

Conditions: Dravet Syndrome
Interventions: zorevunersen, Sham Comparator; Drug · Other
Lead sponsor: Stoke Therapeutics, Inc; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 28
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 23 more

Conditions: Brain Tumor, Brain Necrosis, Brain Metastases, Glioma
Interventions: MRF in conjunction with IVIM MRI without contrast; Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8
Interventions: Biospecimen Collection, Excision, Survey Administration; Procedure · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 5
States / cities: Davis, California • Lexington, Kentucky • Ann Arbor, Michigan + 2 more

Conditions: Acute Myocardial Infarction, Coronary Artery Disease
Interventions: Physiology-guided NCL PCI, Angiography-guided NCL PCI; Procedure
Lead sponsor: Population Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 5,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 14
States / cities: Los Angeles, California • San Francisco, California • Wichita, Kansas + 10 more

Conditions: Immunoglobulin G4 Related Disease
Interventions: Rilzabrutinib, Placebo, Glucocorticoid; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 21
States / cities: Fontana, California • Sacramento, California • San Jose, California + 18 more

Conditions: Autoimmune Haemolytic Anaemia
Interventions: rilzabrutinib, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 27
States / cities: Phoenix, Arizona • Tucson, Arizona • Duarte, California + 23 more

Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
Interventions: Opevesostat, Dexamethasone, Fludrocortisone acetate, Hydrocortisone, Abiraterone acetate, Prednisone acetate, Enzalutamide; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 63
States / cities: Tucson, Arizona • Irvine, California • Los Angeles, California + 56 more

Conditions: Colitis, Ulcerative
Interventions: Ozanimod; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 36
States / cities: Phoenix, Arizona • Tucson, Arizona • Garden Grove, California + 30 more

Conditions: AML, Adult, MDS
Interventions: Eganelisib, Eganelisib in combination with cytarabine, Eganelisib in combination with azacitidine, Azacitadine (AZA); Drug
Lead sponsor: Stelexis BioSciences; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 10
States / cities: Duarte, California • Aurora, Colorado • Tampa, Florida + 6 more

Conditions: Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Breast Neoplasms, Non-Small-Cell Lung Neoplasms, Ovarian Neoplasm, Advanced Solid Tumor
Interventions: BT8009, Pembrolizumab; Drug
Lead sponsor: BicycleTx Limited; Industry
Eligibility: 18 Years and older
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 9
States / cities: Denver, Colorado • Ocala, Florida • Orlando, Florida + 6 more

Conditions: Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
Interventions: Biospecimen Collection, Olutasidenib; Procedure · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Duarte, California • Cleveland, Ohio

Conditions: Biliary Tract Cancer, Biliary Tract Neoplasms, Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma
Interventions: Trifluridine/tipiracil, Oxaliplatin; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 19 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Cleveland, Ohio

Clinical trials in Cleveland, Ohio

Filter and sort this location

Institutions in Cleveland

Live official records

A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

Development of MRF for Characterization of Brain Tumors After Radiotherapy

Narrow Excision Versus Wide Excision for the Treatment of Adults With Invasive Cutaneous Melanoma, ICEMAN Trial

Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease

A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease

A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDS

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer